Zymeworks Quarterly Cash Flow Statement
NASDAQ: ZYMEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Zymeworks free cash flow
In the quarter ended Jun 30, 2026, Zymeworks generated -$31.9 million of operating cash flow and spent $0 on capital expenditures. That left free cash flow of -$31.9 million, a free-cash-flow margin of -696.0% of revenue. Free cash flow was down 376.4% from the prior year's $11.6 million.
Zymeworks returned $51.9 million to shareholders through share repurchases.
Summary generated from market data by MetaCap's automated system. Methodology
Zymeworks cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -45.02M | -44.16M | -41.21M | -19.60M | 2.32M | -22.64M | -23.51M | -29.85M | -37.69M | -31.65M | -14.48M | -28.69M |
| Net Income growth (YoY) | -2042.99% | — | — | — | — | — | — | — | — | — | -104.68% | — |
| Depreciation & Amortization | 957.00K | 963.00K | 898.00K | 905.00K | 885.00K | 981.00K | 997.00K | 1.03M | 1.09M | 1.06M | 1.54M | 2.40M |
| Stock-Based Compensation | 11.33M | 6.93M | 8.85M | 6.91M | 5.87M | 6.40M | 5.02M | 4.66M | 4.55M | 3.55M | 3.37M | 2.04M |
| Change in Working Capital | -5.50M | -9.85M | 20.15M | -20.73M | 690.00K | 10.78M | -24.22M | 17.31M | -4.38M | -9.68M | 21.40M | -20.69M |
| Operating Cash Flow | -31.95M | -45.72M | -10.26M | -31.41M | 12.07M | -3.41M | -41.51M | -5.88M | -24.99M | -37.67M | 13.93M | -42.67M |
| Capital Expenditures | 0 | -216.00K | -581.00K | -410.00K | -514.00K | -16.00K | -314.00K | -899.00K | -593.00K | -185.00K | -356.00K | -930.00K |
| Investing Cash Flow | 17.07M | 69.96M | 5.37M | 368.00K | 8.74M | 12.18M | -6.21M | 72.26M | -19.97M | -7.32M | -1.34M | -7.02M |
| Share Repurchases | -51.95M | -76.15M | -25.48M | -16.22M | 0 | 0 | -9.43M | — | — | — | 0 | — |
| Financing Cash Flow | -50.02M | 178.79M | -18.74M | -2.45M | 1.32M | 1.32M | -8.64M | -14.98M | 1.05M | 2.13M | 50.63M | 1.90M |
| Net Change in Cash | -64.87M | 203.13M | -23.68M | -33.42M | 22.05M | 10.10M | -56.25M | 51.39M | -43.85M | -42.74M | 63.23M | -47.77M |
| Free Cash Flow | -31.95M | -45.93M | -10.84M | -31.82M | 11.56M | -3.42M | -41.82M | -6.78M | -25.59M | -37.86M | 13.58M | -43.60M |
This table shows 12 quarterly periods of Zymeworks's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ZYME's reporting calendar. What is a cash flow statement?